OJEMDA

This brand name is authorized in United States.

Active ingredients

The drug OJEMDA contains one active pharmaceutical ingredient (API):

`1`	Tovorafenib UNII `ZN90E4027M` - TOVORAFENIB
	Tovorafenib is a Type II RAF kinase inhibitor of mutant BRAF V600E, wild-type BRAF, and wild-type CRAF kinases. Tovorafenib exhibited antitumor activity in cultured cells and xenograft tumor models harboring BRAF V600E and V600D mutations, and in a xenograft model harboring a BRAF fusion.
	Read more about Tovorafenib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
OJEMDA Tablet / Oral suspension	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	82950-001, 82950-012

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.